Deepak Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.70 M
as on 15-07-2024
- Paid Up Capital ₹ 0.51 M
as on 15-07-2024
- Company Age 23 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -32.71%
(FY 2022)
- Profit -95.73%
(FY 2022)
- Ebitda 40.33%
(FY 2022)
- Net Worth
- Total Assets 0.81%
(FY 2022)
About Deepak Pharma
The Corporate was formerly known as Deepak Pharma Chem Private Limited. The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.70 M and a paid-up capital of Rs 0.51 M, as per Ministry of Corporate Affairs (MCA) records.
Vikas Agarwal, Deepak Agarwal, and Shri Agarwal serve as directors at the Company.
- CIN/LLPIN
U24232RJ2001PTC017156
- Company No.
017156
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Aug 2001
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Udaipur, Rajasthan, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Deepak Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikas Agarwal  | Director | 02-Apr-2003 | Current |
| Deepak Agarwal | Director | 27-Aug-2001 | Current |
| Shri Agarwal | Director | 17-Jan-2011 | Current |
Financial Performance of Deepak Pharma.
Deepak Pharma Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 32.71% decrease. The company also saw a substantial fall in profitability, with a 95.73% decrease in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth | |||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Deepak Pharma?
In 2019, Deepak Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Deepak India Private LimitedActive 24 years 8 daysDeepak Agarwal and Shri Agarwal are mutual person
Vidsa Inorganics Private LimitedActive 26 years 10 monthsVikas Agarwal, Deepak Agarwal and 1 more are mutual person
- Vidsa Agro Private LimitedActive 18 years 3 months
Vikas Agarwal, Deepak Agarwal and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Deepak Pharma?
Unlock and access historical data on people associated with Deepak Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Deepak Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Deepak Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
